- Reference code :
- wf345
- Published date :
-
20 September 2000
- Expired date :
-
06 February 2028
AstraZeneca announced today that it has filed a lawsuit in Pennsylvania against Mutual Pharmaceutical Company, Inc. for patent infringement.
The lawsuit is the result of an Abbreviated New Drug Application (ANDA) filed by Mutual with the U.S. Food and Drug Administration (FDA) concerning Mutual's intent to market a generic version of felodipine in the US. Felodipine is marketed in the US and internationally by AstraZeneca under the brand name Plendil®. Plendil is a long-acting calcium channel blocker.
The basis for AstraZeneca's complaint is that the action by Mutual infringes upon a formulation patent for Plendil, which provides protection to the year 2007. The substance patent for felodipine, which expires in 2001, has not been challenged by Mutual. AstraZeneca intends to fully enforce all of its patents.
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 Lucy Williams +44 (0)20 7304 5034 |
Note to News Editors: |
|
|
|
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
